// App-Quantinova.ai

1726 : Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Researchers

Presenter

  • Lanetta Bronte-Hall

Principal Investigators

  • Biree Andemariam

  • Blyden Gershwin

  • Sanne Lugthart

  • Timothy Mant

  • Jo Howard

  • Henry Fok

  • Perla Eleftheriou

  • Robert Ward Hagar

  • James Mason

  • Rahul Ballal

  • Joelle Lufkin

  • Eleanor Lisbon

Medical Centers

  • Foundation for Sickle Cell Disease Research, Hollywood, FL

  • University of Connecticut, Farmington, CT

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Kings College London, London, United Kingdom

  • UCSF Benioff Childrens Hospital Oakland, Oakland, CA

  • Baylor Scott and White Hospital, Temple, TX

  • Imara, Boston, MA

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

  • Thalassemia

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxyurea

  • Hydroxycarbamide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved